Webinar information
If you are having trouble viewing the webinar video, please try clearing your browser’s cookies/cache.
While cardiovascular (CV) genetics was the first subspecialty to introduce large-scale multi-gene panels, it was also the first to experience an important downstream effect. This resulted in a wave of results that, we would soon learn, were not all that they seemed.
The last decade has led cardiovascular genetic testing down a winding and bumpy road.
Multiple efforts have been made over the years to streamline genetic testing: significantly improving testing and interpretation technology, standardizing variant classification, and shedding light on the increasingly recognized “genes of uncertain significance.”
With so many laboratories to choose from, healthcare professionals should have high expectations of the CV genetics offering from these companies.
Genetic Testing for Cardiovascular Diseases
After watching this webinar, you will be better able to navigate your cardiovascular genetic testing options with the end goal of choosing a trustworthy test with the highest likelihood of yielding an informative result for your patient and family.
Key Objectives:
- Outline the important quality coverage metrics to consider when choosing a cardiovascular gene panel
- Review the existing limitations in the analysis of certain cardiac-specific genes
- Demonstrate the steps taken to build a carefully curated, clinically relevant cardiac gene panel
Read more about our options for cardiovascular diseases here.
Webinar video and content: Copyright © 2020 Blueprint Genetics. All trademarks are property of their respective owners.
Speakers
Tero-Pekka Alastalo
Tero-Pekka is the Executive Director of Medical, and also a co-founder at Blueprint Genetics. He is based in San Francisco and holds various responsibilities in the North American operations of the company. Tero-Pekka has an MD-PhD degree and is specialized in pediatrics and pediatric cardiology. He has a PhD in molecular and cellular biology as well. During his 3-year postdoctoral training at Stanford University School of Medicine, he focused on the molecular genetic mechanisms of cardiovascular disease.
Julie Hathaway
Julie Hathaway received her masters of science in Genetic Counseling from the University of Toronto. She is board certified in both the US and Canada. She was introduced to cardiac genetics early on in her career and this remains her main area of interest in the field. As a Clinical Liaison at Blueprint Genetics, Julie provides both internal and external clinical support and education. In addition, she contributes to research and creating scientific content. Prior to this, she worked as a clinical coordinator and cardiac genetic counselor and worked to establish the multidisciplinary BC Inherited Arrhythmia Program.